- Bydureon pen gets FDA approval
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study: Participation in diabetes education associated with greater ability to self-manage
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said Wednesday.
The FDA announced the approval of Farxiga (dapagliflozin) tablets, designed for use with exercise and dietary adjustments to control blood sugar. Type 2 diabetes affects about 24 million people in the United States, accounting for more than 90% of diabetes cases.
"Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and Farxiga provides an additional treatment option for millions of Americans with Type 2 diabetes," FDA Office of Drug Evaluation II director Curtis Rosebraugh said.
The drug belongs to a class known as sodium-glucose co-transporter 2, or SGLT2, inhibitor. The drug works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion and thereby lowering blood glucose levels.